Frequently Asked
Questions (FAQ)

Answers to the most common questions about the BD Veritor™ Plus System testing experience.


Contact Us


Background Image


COVID-19 is a contagious respiratory illness caused by the SARS-CoV-2 virus. COVID-19 can present as a mild to severe illness, although some people infected with COVID-19 may have no symptoms at all. Older adults and people of any age who have underlying medical conditions have a higher risk of severe illness from COVID-19. Serious outcomes of COVID-19 include hospitalization and death. Regardless of vaccination status, the SARS-CoV-2 virus can be spread to others not just while one is sick, but even before a person shows signs or symptoms of being sick (eg, fever, coughing, difficulty breathing).


A full list of symptoms of COVID-19 can be found at:

There are a variety of different testing options for COVID-19, including for individuals with and without symptoms. For more information on current CDC recommendations for COVID-19 testing, please visit:

An antigen test is a diagnostic test that detects specific proteins from the virus that causes COVID-19. An antigen test is also commonly referred to as a rapid test. For more information on the different types of testing available for COVID‑19, please visit:

COVID-19 serial testing is when one person tests themselves at least twice for COVID-19, such as every other day. By testing more frequently, you may detect COVID-19 more quickly and reduce the spread of infection.

It is possible for a fully vaccinated individual to become infected and transmit COVID-19 to other individuals, as none of the currently approved vaccines are 100% effective in preventing infection with COVID-19. CDC recommends that fully vaccinated individuals get tested if they are experiencing COVID-19 symptoms or if they had close contact with a confirmed positive individual. For more information on current CDC recommendations for COVID-19 testing, please visit:


Reimbursement FAQ

Up-to-date CPT code information can be found at Information for SARS-CoV-2 can be found under the “COVID-19” section. Information for other BD Veritor™ Plus System assays can be found under the “Point of Care” section. 

CMS issued G2023 and G2024 to allow “independent clinical diagnostic laboratories” to bill for COVID-19 specimen collection. Physician offices that are billing an E/M code for COVID-19 patient management and specimen collections should not bill additional specimen collection codes. Please see the CMS FAQ for more details on Medicare Fee-for-Service billing.

Please see the COVID-19 Frequently Asked Questions (FAQs) on Medicare Fee-for-Service Billing published by the Centers for Medicare and Medicaid Services.

Yes, the –QW modifier has been issued for 87426. Please see CMS Manual System Transmittal 10231.


Contact a Sales Representative
to get your organization's diagnostic testing program started today

* The BD Veritor™ System for Rapid Detection of SARS-CoV-2 is intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct anterior nasal swabs from individuals who are either suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.

This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories.

RSV=respiratory syncytial virus; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.

This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens.

This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.

 Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests.  This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.